In a new 13F filing, healthcare-focused investment firm Deerfield Management revealed it has established a significant position in Mineralys Therapeutics (MLYS). The filing, made public on August 14, 2026, shows the firm acquired 3.96 million shares, valued at approximately $106.79 million, giving it a 1.11% weight in its reported portfolio.
This disclosure reflects holdings as of June 30, 2026, and does not represent a real-time trade. Mineralys Therapeutics is a biopharmaceutical company developing a treatment for hypertension. During the second quarter, the company completed a $150 million follow-on public offering and continued to advance the FDA review of its lead drug candidate, lorundrostat.